Search research articles
Contact Us
Filters
Showing results (301-310 of 410) with videos related to
Page
of 41
Sort By:
The Lancet. Oncology
|
February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Matthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
The Lancet. Oncology
|
September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi, Howard I Scher, Arturo Molina, et al.
The Lancet. Oncology
|
November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Imaging Neuroscience (Cambridge, Mass.)
|
January 8, 2026
TissUnet: Improved extracranial tissue and cranium segmentation for children through adulthood
Markiian Mandzak, Elvira Yang, Anna Zapaishchykova, et al.
The Lancet. Oncology
|
October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
Neeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
Nature Communications
|
January 9, 2021
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
Gillian Vandekerkhove, Jean-Michel Lavoie, Matti Annala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
Joaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
S Chowdhury, A Bjartell, N Agarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
Evan Y Yu, Hongli Li, Celestia S Higano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer
S Halabi, S Dutta, C M Tangen, et al.
Page
of 41
Search research articles
Search
Showing results (301-310 of 410) with videos related to
Sort By:
Page
of 41
The Lancet. Oncology
|
February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Matthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
The Lancet. Oncology
|
September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi, Howard I Scher, Arturo Molina, et al.
The Lancet. Oncology
|
November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Imaging Neuroscience (Cambridge, Mass.)
|
January 8, 2026
TissUnet: Improved extracranial tissue and cranium segmentation for children through adulthood
Markiian Mandzak, Elvira Yang, Anna Zapaishchykova, et al.
The Lancet. Oncology
|
October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
Neeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
Nature Communications
|
January 9, 2021
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
Gillian Vandekerkhove, Jean-Michel Lavoie, Matti Annala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
Joaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
S Chowdhury, A Bjartell, N Agarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
Evan Y Yu, Hongli Li, Celestia S Higano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer
S Halabi, S Dutta, C M Tangen, et al.
Page
of 41